Selected Publications

Kim A. Reiss, MD; Mark H. O’Hara, MD; Ursina Teitelbaum, MD; Thomas B. Karasic, MD; Charles Schneider, MD; Caroline F. Pratz, CRNP; Katharine Nathanson, MD; Robert H. Vonderheide, MD, DPhil; Susan M. Domchek, MD: A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update ASCO GI, San Francisco, CA : 2024.

Alison M. Schram, Teresa Macarulla, James Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii-Saab, Jordi Rodon, Koichi Goto, Sun Young Rha, Michael Duruisseaux, Natasha Leighl, Benjamin A. Weinberg, Mohammed Najeeb Al Hallak, Andrew K. Joe, Shola Adeyemi, Ernesto Wasserman, Kees-Jan Koeman, Alexander E. Drilon, Eileen M. O’Reilly: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) ESMO 2023, Madrid, Spain : 2023.

Dylane Wineland, Anh N. Le, Ryan Hausler, Gregory Kelly, Emanuel Barrett, Heena Desai, Brad Wubbenhors3, John Pluta, Paul Bastian, Heather Symecko, Kurt D’Andrea, Abigail Doucette, Peter Gabriel, Kim A. Reiss, Anupma Nayak, Michael Feldman, Susan M. Domchek, Katherine L. Nathanson, Kara N. Maxwell: Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers JCO Precision Oncology : 2023.

Timothy J Brown, MD, Arielle Yablonovitch, PhD, Jacob E Till MD PhD, Jennifer Yen, PhD, Lesli A. Kiedrowski, MS MPH, Ryan Hood BA, Mark H. O’Hara MD, Ursina Teitelbaum MD, Thomas B. Karasic MD, Charles Schneider MD, Erica L. Carpenter, PhD MBA, Katherine Nathanson MD, Susan M. Domchek MD, and Kim A. Reiss MD: The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib Clin Cancer Res : 2023.

Kim A. Reiss, MD; Sung Chul Hong, MS; Anup K. Kasi, MD; Eileen M. O’Reilly, MD; Shishir K Maithel, MD; Xin Yao, MD; Stanley R Hamilton, MD; Ben Boursi, MD; Michael J. Pishvaian, MD; Samuel J. Klempner, MD; Susan M. Domchek, MD; Paul Catalano, ScD; Elena G. Chiorean, MD; Philp A. Philip, MD; Peter J. O’Dwyer, MD: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation: ECOG-ACRIN EA2192 ASCO 2023, Chicago, IL : 2023.

Vincent Chung, Katherine A Guthrie, Michael J Pishvaian, Kim A. Reiss, Andrew M Lowy, Davendra P Sohal, Sarah Colby, Elad Sharon, Carmen Allegra, Eileen M O'Reilly, E Gabriela Chiorean, Philip A Philip: Randomized Phase II Trial of Olaparib Plus Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations: SWOG S2001 ASCO 2023, Chicago, IL : 2023.

Caroline Salafia, Malwina Lewicka, Heather Symecko, Kelsey Spielman, Kelsey Breen, Rebecca Mueller, Amanda Catchings, Magan Trottier, Erin E. Salo-Mullen, Ibrahim Shah, Anna Arutyunova, Melissa Batson, Stacy Pundock, Elizabeth Schofield, Kenneth Offit, Zsofia K. Stadler, Maria I. Carlo, Vivek Narayan, Kim A. Reiss, Mark E. Robson, Susan M. Domchek, and Jada G. Hamilton, Ph.D: Impact of COVID-19 pandemic point-of-care genetic testing of advanced cancer patients IMPAHC 2023, Washington, DC : 2023.

Caroline Salafia, M.A; Malwina Lewicka, Ph.D; Heather Symecko, M.P.H; Kelsey Spielman, M.S., C.G.C., Kelsey Breen, M.S., M.Sc., C.G.C.; Rebecca Mueller, M.S., C.G.C.; Amanda Catchings, M.S., C.G.C.; Magan Trottier, M.Sc., M.Sc., C.G.C.; Erin E. Salo-Mullen, M.S., M.P.H., C.G.C.; Ibrahim Shah, B.A; Anna Arutyunova, B.S.; Melissa Batson, M.P.H.; Stacy Pundock, B.A.; Elizabeth Schofield, D.P.H.; Kenneth Offit, M.D., M.P.H.; Zsofia K. Stadler, M.D.; Maria I. Carlo, M.D.; Vivek Narayan M.D. ; Kim A. Reiss, M.D.; Mark E. Robson, M.D.; Susan M. Domchek, M.D.; Jada G. Hamilton, Ph.D., M.P.H.: Impact of ambiguity aversion on genetic testing concerns following “mainstreaming” hereditary cancer multigene panel testing IMPAHC 2023, Washington, DC : 2023.

Samuele Cannas et al: Liquid biopsy signature combining copy number instability and mutant KRAS detection is associated with survival for patients with metastatic pancreatic cancer AACR 2023, Orlando, FL : 2023.

Kim A. Reiss, MD; Sung Chul Hong, MS; Anup K. Kasi, MD; Eileen M. O’Reilly, MD; Shishir K Maithel, MD; Xin Yao, MD; Stanley R Hamilton, MD; Ben Boursi, MD; Michael J. Pishvaian, MD; Samuel J. Klempner, MD; Susan M. Domchek, MD; Paul Catalano, ScD; Elena G. Chiorean, MD; Philp A. Philip, MD; Peter J. O’Dwyer, MD: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation: ECOG-ACRIN EA2192 ASCO GI, San Francisco, CA : 2023.

Academic Contact Information

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone: 215-360-0735
Patient appointments: 800-789-7366